Making the invisible visible: improving detectability of MRI-invisible residual cervical cancer after conisation by DCE-MRI

被引:9
|
作者
Huang, J-W [1 ]
Song, J-C [1 ]
Chen, T. [1 ]
Yang, M. [1 ]
Ma, Z-L [1 ]
机构
[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Radiol, Nanjing, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
Cervical cancer; Conization; Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI); Residual tumor; CARCINOMA; TUMORS;
D O I
10.1016/j.crad.2018.10.013
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
AIM: To determine whether dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) quantitative parameters increase the detectability of MRI-invisible residual cervical cancer after conisation. MATERIALS AND METHODS: This retrospective study included 59 patients with MRI-invisible cervical cancer, but positive conisation pathology. Thirty-five patients were confirmed to have residual cervical cancer, and 24 patients showed non-residual cervical cancer. DCE-MRI quantitative parameters were calculated in the anterior or posterior cervix according to the conisation position. Receiver operating characteristic (ROC) analysis was used to find the threshold of DCE-MRI parameters in differentiate residual cervical cancer patients from non-residual cervical cancer patients after conisation. RESULTS: For patients with residual cervical cancer, the K(trans )and V-e values were significantly higher than in their counterparts with non-residual cervical cancer (0.610 +/- 0.395 versus 0.366 +/- 0.305/min, p=0.013; and 0.703 +/- 0.270 versus 0.540 +/- 0.280%, p=0.028; respectively). The K-trans showed the highest area under the ROC curve (AUC) of 0.705 (p=0.004) with a sensitivity of 67.6% and specificity of 68%. CONCLUSION: DCE-MRI quantitative parameters increased the detectability of MRI-invisible residual cervical cancer after conisation. (C) 2018 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:166.e15 / 166.e21
页数:7
相关论文
共 49 条
  • [1] THE MRI-INVISIBLE PROSTATE CANCER: INCIDENCE AND SIGNIFICANCE
    Wu, Jason
    Margolis, Daniel
    Natarajan, Shyam
    Priester, Alan
    Huang, Jiaoti
    Macairan, Maria Luz
    Lieu, Patricia
    Sharma, Devi
    Dorey, Frederick
    Marks, Leonard
    [J]. JOURNAL OF UROLOGY, 2016, 195 (04): : E175 - E176
  • [2] Invisible fat on CT: making it visible by MRI
    Unal, Emre
    Karaosmanoglu, Ali Devrim
    Akata, Deniz
    Ozmen, Mustafa Nasuh
    Karcaaltincaba, Musturay
    [J]. DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY, 2016, 22 (02) : 133 - 140
  • [3] Histopathological Features of MRI-Invisible Regions of Prostate Cancer Lesions
    van Houdt, Petra J.
    Ghobadi, Ghazaleh
    Schoots, Ivo G.
    Heijmink, Stijn W. T. P. J.
    de Jong, Jeroen
    van der Poel, Henk G.
    Pos, Floris J.
    Rylander, Susanne
    Bentzen, Lise
    Haustermans, Karin
    van der Heide, Uulke A.
    [J]. JOURNAL OF MAGNETIC RESONANCE IMAGING, 2020, 51 (04) : 1235 - 1246
  • [4] Partial gland ablation outcomes for localized prostate cancer in patients with MRI-visible and MRI-invisible lesions.
    Zhu, Alec
    Gereta, Sofia
    Stangl-Kremser, Judith
    Margolis, Daniel
    Borregales, Leonardo Daniel
    Basourakos, Spyridon P.
    McClure, Timothy D.
    Hu, Jim C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [5] Partial-gland Cryoablation Outcomes for Localized Prostate Cancer in Patients with Magnetic Resonance Imaging (MRI)-visible and MRI-invisible Lesions
    Zhu, Alec
    Gereta, Sofia
    Zhang, Tenny R.
    Stangl-Kremser, Judith
    Mora, Richard M.
    Margolis, Daniel J. A.
    Hu, Jim C.
    [J]. EUROPEAN UROLOGY OPEN SCIENCE, 2023, 53 : 38 - 45
  • [6] Preoperative Assessment of MRI-Invisible Early-Stage Endometrial Cancer With MRI-Based Radiomics Analysis
    Jiang, Xiaoting
    Song, Jiacheng
    Zhang, Aining
    Cheng, Wenjun
    Duan, Shaofeng
    Liu, Xisheng
    Chen, Ting
    [J]. JOURNAL OF MAGNETIC RESONANCE IMAGING, 2023, 58 (01) : 247 - 255
  • [7] Comparative Analysis of Histologic and Molecular Features of MRI-Visible and MRI-Invisible Gleason Score 3+4=7 Prostate Cancer
    Yilmaz, Helene
    Purysko, Andrei
    Haddad, Zaid
    Takhar, Mandeep
    Yousefi, Kasra
    Erho, Nicholas G.
    Palmer-Arontsen, Beatrix
    Davicioni, Elai
    McKenney, Jesse K.
    Przybycin, Christopher
    Klein, Eric A.
    Magi-Galluzzi, Cristina
    [J]. MODERN PATHOLOGY, 2017, 30 : 269A - 269A
  • [8] Comparative Analysis of Histologic and Molecular Features of MRI-Visible and MRI-Invisible Gleason Score 3+4=7 Prostate Cancer
    Yilmaz, Helene
    Purysko, Andrei
    Haddad, Zaid
    Takhar, Mandeep
    Yousefi, Kasra
    Erho, Nicholas G.
    Palmer-Arontsen, Beatrix
    Davicioni, Elai
    McKenney, Jesse K.
    Przybycin, Christopher
    Klein, Eric A.
    Magi-Galluzzi, Cristina
    [J]. LABORATORY INVESTIGATION, 2017, 97 : 269A - 269A
  • [9] Patient- and tumor-level risk factors for MRI-invisible prostate cancer
    Kuhlmann, Paige K.
    Chen, Michelle
    Luu, Michael
    Naser-Tavakolian, Aurash
    Patel, Devin N.
    Kim, Hyung L.
    Saouaf, Rola
    Daskivich, Timothy J.
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (03) : 794 - 801
  • [10] Patient- and tumor-level risk factors for MRI-invisible prostate cancer
    Paige K. Kuhlmann
    Michelle Chen
    Michael Luu
    Aurash Naser-Tavakolian
    Devin N. Patel
    Hyung L. Kim
    Rola Saouaf
    Timothy J. Daskivich
    [J]. Prostate Cancer and Prostatic Diseases, 2021, 24 : 794 - 801